Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | OTC | P00480 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
| ▸ | ARG1 | P05089 | 3/20 | 0.37 |
| ▸ | ARG2 | P78540 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26009500 | 1.00 | DRD2 (0.43) | DRD2DRD3OTCGSRFOLH1 | |
| SCHEMBL25357414 | 1.00 | DRD2 (0.43) | DRD2DRD3OTCGSRFOLH1 | |
| SCHEMBL25358822 | 0.99 | DRD2 (0.42) | DRD2DRD3OTCGSRFOLH1 | |
| SCHEMBL25358812 | 0.99 | DRD2 (0.42) | DRD2DRD3OTCGSRFOLH1 | |
| SCHEMBL26008338 | 0.91 | DRD2 (0.41) | DRD2DRD3FOLH1ALBTPSAB1 | |
| SCHEMBL25357058 | 0.90 | EPHX2 (0.41) | DRD2DRD3GSRTPSAB1 | |
| SCHEMBL25357049 | 0.90 | EPHX2 (0.41) | DRD2DRD3GSRTPSAB1 | |
| SCHEMBL26009439 | 0.90 | DRD2 (0.40) | DRD2DRD3FOLH1TPSAB1TPSD1 | |
| SCHEMBL26008122 | 0.89 | DRD2 (0.41) | DRD2DRD3OTCGSRTPSAB1 | |
| SCHEMBL26008115 | 0.89 | DRD2 (0.41) | DRD2DRD3OTCGSRTPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025100520-A1 | PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE | ペプチドリーム株式会社 | 2025-05-15 | — | — | WO | claimed |
| CN-117957310-A | Method for producing organoid, culture medium for organoid production, organoid, and method for evaluating test substance | JSR株式会社 | 2024-04-30 | — | — | CN | claimed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC (JP) | 2026-04-09 | — | — | US | disclosed |
| EP-4667483-A1 | HUMAN TRANSFERRIN RECEPTOR-BINDING PEPTIDE | JCR Pharmaceuticals Co., Ltd. (JP) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025100520-A1 | PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE | ペプチドリーム株式会社 | 2025-05-15 | — | — | WO | disclosed |
| WO-2025070731-A1 | PEPTIDEPEPTIDE | ペプチドリーム株式会社 | 2025-04-03 | — | — | WO | disclosed |
| WO-2025070720-A1 | PEPTIDE | ペプチドリーム株式会社 | 2025-04-03 | — | — | WO | disclosed |
| EP-4410816-A1 | PEPTIDE | PeptiDream Inc. (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-118103387-A | Peptides | 肽梦想株式会社 | 2024-05-28 | — | — | CN | disclosed |
| CN-117957310-A | Method for producing organoid, culture medium for organoid production, organoid, and method for evaluating test substance | JSR株式会社 | 2024-04-30 | — | — | CN | disclosed |
| CN-117957240-A | Human transferrin receptor binding peptides | 肽梦想株式会社 | 2024-04-30 | — | — | CN | disclosed |
| WO-2024073622-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| CN-117677628-A | GHR binding pending peptides and compositions comprising the same | 肽梦想株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| WO-2023054659-A1 | ORGANOID PRODUCTION METHOD, CULTURE MEDIUM FOR ORGANOID PRODUCTION, ORGANOID, AND TEST SUBSTANCE EVALUATION METHOD | JSR株式会社 | 2023-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | DRD2 3504/4885DRD3 3493/4885OTC 2109/4885 |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | EPHA2, EPHA1, EPHB1 | DRD2 4054/4885DRD3 4287/4885OTC 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.